Cervix Cancer, Image, Body
Conditions
Keywords
PET/MRI, Imaging technique, Cervix Cancer, FLT PET radiotracer, Response assessment, Radiation treatment
Brief summary
This pilot study aims to monitor early tumour response based on \[18F\]FLT-PET/MRI scans and to determine the feasibility of personalised radiotherapy to spare active bone marrow areas identified by \[18F\]FLT-PET/MRI. Bone marrow within the pelvis will be outlined by employing 18FLT PET to identify active BM within bony structures. Subsequently, treatment plans with various conformal radiotherapy techniques will be generated with different optimization approaches toward bone marrow while ensuring adequate tumor coverage. Dosimetric comparison amongst plans will be carried out.
Interventions
DIAGNOSTIC_TEST[18F]FLT-PET/MRI body scan
\[18F\]FLT-PET/MRI body scan will be done at * Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy. * Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy). At these visits: * Obtain vital signs and weight in kg before FLT administration. * Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.) * Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT. * Perform a saline flush following the FLT injection. * Body PET/MRI will be performed after FLT injection. * Time of injection of FLT and time of scan will need to be recorded.
Sponsors
National Cancer Centre, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Have given written informed consent, with the understanding that consent may be withdrawn at any time without prejudice * Histologically or cytologically confirmed cervical carcinoma * FIGO staged IB to IVA * Underwent MRI pelvis * Underwent FDG-PET/CT or MRI abdomen or CT thorax and abdomen or Chest X ray for routine staging * Planned for radical radiotherapy with or without chemotherapy * No distant metastasis in staging work up * ECOG 0-2 * Age 21 or over (no upper age limit)
Exclusion criteria
* Patients scheduled for neoadjuvant chemotherapy * Patients with previous hysterectomy or radiotherapy to the pelvis * Patients who are pregnant or lactating * Patients who do not meet the above mentioned inclusion criteria * Patients who refuse to give and/or sign the informed consent * Patients who currently have a pacemaker * Patients who have a history of serious adverse events related to a previous MRI or PET/CT * Patients who are unable to undergo MRI scanning * Patients with a known allergy against any component of the contrast enhancing agent * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule; these conditions should be discussed with the patient before registration in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the feasibility of [18F]FLT-PET/MRI imaging for early prediction of treatment by comparison of changes in baseline SUV uptake at Week 4-5 of External Beam Radiotherapy | Baseline (1 to 28 days before prior initiation of radiotherapy) and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
Secondary
| Measure | Time frame |
|---|---|
| Compare SUV uptake of FLT with FDG PET at diagnosis | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| Compare SUV uptake of FLT before and after chemoRT | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| To compare differences in tumor and regional staging between PET/MRI, PET/CT and MRI scans, determined from the tumor size and extent of local involvement | Baseline (1 to 28 days before prior initiation of radiotherapy) and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| To determine the correlation of [18F]FLT parameters as baseline, during treatment and change in [18F] FLT parameters with clinical outcome and response | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| Compare changes in stimulated radiation treatment volume when derived from PET/MRI vs PET/CT vs MRI | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| Compare VMAT versus IMRT versus proton versus tomotherapy for best marrow sparing plan | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
| Assess the feasibility of PET/MRI in the radiation treatment planning workflow with respect to the adequacy of image quality and image fusion of PET/MRI data with the treatment planning CT for marrow sparing RT plan | Through patient treatment completion, an average of 3 months |
Countries
Singapore
Contacts
Primary ContactKiattisa Sommat
Outcome results
None listed